176 related articles for article (PubMed ID: 17879017)
41. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
42. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
43. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
44. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
45. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
46. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
47. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
48. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
49. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
50. The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.
Li CY
Int J Hematol; 2002 Aug; 76 Suppl 2():6-8. PubMed ID: 12430892
[TBL] [Abstract][Full Text] [Related]
51. [Research progress on gene mutation of jak2].
Liu L; Li W; Liu N; Pang L; Feng SX; Zhao LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1629-32. PubMed ID: 20030962
[TBL] [Abstract][Full Text] [Related]
52. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
Vannucchi AM; Guglielmelli P
Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
[No Abstract] [Full Text] [Related]
53. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
54. Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.
Kaushansky K
Cytokine Growth Factor Rev; 2006 Dec; 17(6):423-30. PubMed ID: 17055768
[TBL] [Abstract][Full Text] [Related]
55. Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).
Vladareanu AM; Müller-Tidow C; Bumbea H; Radesi S
Oncol Rep; 2010 Mar; 23(3):595-604. PubMed ID: 20126996
[TBL] [Abstract][Full Text] [Related]
56. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.
Mertens F; Johansson B; Heim S; Kristoffersson U; Mitelman F
Leukemia; 1991 Mar; 5(3):214-20. PubMed ID: 2013980
[TBL] [Abstract][Full Text] [Related]
57. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
59. Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders.
Klippel S; Pahl HL
Pathol Biol (Paris); 2004 Jun; 52(5):267-74. PubMed ID: 15217712
[TBL] [Abstract][Full Text] [Related]
60. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
